|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
tempol inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein] |
CTD |
PMID:25204689 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 mRNA]; tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 protein]; tempol inhibits the reaction [AGT protein results in decreased export of Sodium]; tempol inhibits the reaction [AGT protein results in increased abundance of Oxygen]; tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased expression of RHOA protein]] tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; tempol inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; tempol inhibits the reaction [AGT protein results in increased expression of EDN1 mRNA]; tempol inhibits the reaction [ATP7A mutant form inhibits the reaction [AGT protein results in increased susceptibility to Acetylcholine]]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]]; tempol promotes the reaction [ATOX1 protein inhibits the reaction [AGT protein modified form results in decreased susceptibility to Acetylcholine]] |
CTD |
PMID:14597645 PMID:17391658 PMID:17620961 PMID:18250367 PMID:18768397 PMID:22753205 PMID:29609002 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:17620961 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr1b |
angiotensin II receptor, type 1b |
multiple interactions |
ISO |
tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:17620961 |
|
NCBI chr 2:102,844,969...102,920,232
Ensembl chr 2:102,844,969...102,920,232
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
ISO |
tempol affects the phosphorylation of AKT1 protein |
CTD |
PMID:24550650 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid] tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] |
CTD |
PMID:20530721 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
multiple interactions |
ISO |
tempol promotes the reaction [ATOX1 protein inhibits the reaction [AGT protein modified form results in decreased susceptibility to Acetylcholine]] |
CTD |
PMID:22753205 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
tempol inhibits the reaction [ATP7A mutant form inhibits the reaction [AGT protein results in increased susceptibility to Acetylcholine]]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] |
CTD |
PMID:18768397 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects expression decreases expression |
ISO EXP |
tempol affects the expression of BAX protein tempol results in decreased expression of BAX protein |
CTD |
PMID:18714161 PMID:24550650 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
tempol affects the expression of BCL2 protein |
CTD |
PMID:24550650 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
tempol results in decreased expression of C1QA mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C4b |
complement C4B (Chido blood group) |
decreases expression |
ISO |
tempol results in decreased expression of C4B mRNA |
CTD |
PMID:19555370 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; tempol inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein] |
CTD |
PMID:28633109 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO EXP |
[tempol co-treated with UCF 101 co-treated with acetovanillone] inhibits the reaction [S-Nitrosoglutathione results in increased activity of CASP3 protein]; tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP3 protein] tempol results in decreased expression of CASP3 protein |
CTD |
PMID:18714161 PMID:20153346 PMID:20371263 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP7 protein]; tempol results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:20371263 PMID:26177467 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
EXP |
tempol results in decreased expression of CASP9 protein |
CTD |
PMID:18714161 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein results in increased susceptibility to [tert-Butylhydroperoxide co-treated with Desoxycorticosterone co-treated with tempol] |
CTD |
PMID:12646410 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
EXP |
tempol results in decreased expression of CCN2 mRNA |
CTD |
PMID:16685210 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
tempol results in decreased expression of CCND1 protein |
CTD |
PMID:26177467 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
tempol inhibits the reaction [Superoxides affects the localization of CD38 protein] |
CTD |
PMID:23940720 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
tempol promotes the reaction [CDKN1A protein results in increased susceptibility to Doxorubicin] tempol results in increased expression of CDKN1A protein |
CTD |
PMID:15601469 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ctss |
cathepsin S |
decreases expression |
ISO |
tempol results in decreased expression of CTSS mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 2:183,089,192...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
tempol results in decreased expression of CXCL14 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr17:8,317,933...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
EXP |
tempol results in decreased expression of CYBA mRNA |
CTD |
PMID:16685210 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
decreases expression |
EXP |
tempol results in decreased expression of CYBB; tempol results in decreased expression of CYBB mRNA |
CTD |
PMID:16685210 PMID:20943769 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [CYP2E1 protein results in increased reduction of Tirapazamine] |
CTD |
PMID:7710944 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions |
EXP ISO |
tempol results in decreased expression of EDN1 mRNA; tempol results in decreased expression of EDN1 protein tempol inhibits the reaction [AGT protein results in increased expression of EDN1 mRNA] |
CTD |
PMID:17391658 PMID:28039404 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
affects localization |
ISO |
tempol affects the localization of EPAS1 protein |
CTD |
PMID:24755467 |
|
NCBI chr 6:7,790,236...7,871,246
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases response to substance |
ISO |
tempol results in decreased susceptibility to FANCD2 gene mutant form |
CTD |
PMID:22628295 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Foxo3 |
forkhead box O3 |
affects phosphorylation |
ISO |
tempol affects the phosphorylation of FOXO3 protein |
CTD |
PMID:24550650 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
tempol inhibits the reaction [Aldosterone results in increased expression of GCLC protein] |
CTD |
PMID:24512358 PMID:25204689 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[tempol co-treated with Tobacco Smoke Pollution] results in increased expression of GPX2 mRNA; tempol promotes the reaction [Tobacco Smoke Pollution results in increased expression of GPX2 protein] |
CTD |
PMID:32726580 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression |
ISO |
tempol results in increased expression of GPX4 mRNA |
CTD |
PMID:22221582 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of GSR protein] |
CTD |
PMID:15925750 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
EXP |
tempol inhibits the reaction [Sodium Chloride results in increased expression of HIF1A protein] tempol results in increased expression of HIF1A protein |
CTD |
PMID:12595275 PMID:20232302 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
tempol inhibits the reaction [Asbestos, Crocidolite results in decreased activity of HMGCR protein]; tempol inhibits the reaction [Vitamin K 3 results in decreased activity of HMGCR protein] |
CTD |
PMID:21257924 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
tempol results in increased expression of HMOX1 mRNA [tempol co-treated with Tobacco Smoke Pollution] results in increased expression of HMOX1 mRNA |
CTD |
PMID:12595275 PMID:32726580 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
tempol inhibits the reaction [PRKAA2 protein affects the expression of HSPA5 protein] |
CTD |
PMID:21145922 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
multiple interactions |
ISO |
[tempol co-treated with UCF 101 co-treated with acetovanillone] inhibits the reaction [S-Nitrosoglutathione affects the localization of HTRA2 protein] |
CTD |
PMID:20153346 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
decreases expression |
ISO |
tempol results in decreased expression of IKBKE protein |
CTD |
PMID:26177467 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IL10 mRNA] |
CTD |
PMID:32726580 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL17A mRNA] |
CTD |
PMID:32726580 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [Phenol results in decreased expression of IL1B mRNA] tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL1B mRNA] |
CTD |
PMID:16785328 PMID:32726580 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL6 mRNA] tempol inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of and results in increased secretion of IL6 protein] |
CTD |
PMID:24296301 PMID:32726580 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
increases expression |
ISO |
tempol results in increased expression of IREB2 protein |
CTD |
PMID:18073202 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
tempol inhibits the reaction [Benzene results in decreased phosphorylation of IRS2 protein] |
CTD |
PMID:30346588 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
tempol inhibits the reaction [Paraquat results in increased expression of JUN mRNA] |
CTD |
PMID:7662713 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] |
CTD |
PMID:20530721 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
tempol inhibits the reaction [LEP protein results in decreased activity of PON1 protein] |
CTD |
PMID:15829432 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
tempol inhibits the reaction [LEPR gene mutant form results in decreased susceptibility to Acetylcholine] |
CTD |
PMID:19478208 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tempol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20056918 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tempol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20056918 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir322 |
microRNA 322 |
multiple interactions |
ISO |
tempol inhibits the reaction [Glucose results in decreased expression of MIR322] |
CTD |
PMID:25516495 |
|
NCBI chr X:132,806,594...132,806,688
Ensembl chr X:132,806,594...132,806,688
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity |
EXP |
tempol results in increased activity of MMP2 protein |
CTD |
PMID:17196988 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity |
EXP |
tempol results in increased activity of MMP9 protein |
CTD |
PMID:17196988 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of and results in increased activity of MPO protein] |
CTD |
PMID:32726580 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
tempol inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] |
CTD |
PMID:25204689 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [copper histidine results in increased activity of NFKB1 protein]; tempol inhibits the reaction [Copper results in increased activity of NFKB1 protein] |
CTD |
PMID:16987042 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
tempol inhibits the reaction [Particulate Matter results in decreased expression of NFKBIA protein] |
CTD |
PMID:27128347 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tempol results in increased phosphorylation of NOS1 protein]; tempol inhibits the reaction [lead acetate results in increased expression of NOS1 protein]; tempol inhibits the reaction [Phenol results in decreased expression of NOS1 mRNA] |
CTD |
PMID:11454931 PMID:16785328 PMID:20056918 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
tempol inhibits the reaction [copper histidine results in increased expression of NOS2 protein]; tempol inhibits the reaction [Copper results in increased expression of NOS2 protein]; tempol inhibits the reaction [lead acetate results in increased expression of NOS2 protein] |
CTD |
PMID:11454931 PMID:16987042 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [lead acetate results in increased expression of NOS3 protein]; tempol inhibits the reaction [Sodium Chloride results in decreased expression of NOS3 protein] |
CTD |
PMID:11230275 PMID:11454931 PMID:20232302 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [Paraquat results in increased activity of ODC1 protein] |
CTD |
PMID:7662713 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pah |
phenylalanine hydroxylase |
decreases expression |
ISO |
tempol results in decreased expression of PAH mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [sodium arsenite results in increased expression of PECAM1 protein] |
CTD |
PMID:19033667 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [LEP protein results in decreased activity of PON1 protein] |
CTD |
PMID:15829432 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
tempol inhibits the reaction [PRKAA2 protein affects the expression of HSPA5 protein] |
CTD |
PMID:21145922 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [Glucose results in decreased expression of PRKG1 protein] |
CTD |
PMID:17320767 |
|
NCBI chr 1:228,409,883...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
tempol inhibits the reaction [Ketoconazole results in increased expression of PRKN mRNA]; tempol inhibits the reaction [Ketoconazole results in increased expression of PRKN protein] |
CTD |
PMID:25787151 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
tempol inhibits the reaction [copper histidine results in increased expression of PTGS2 mRNA]; tempol inhibits the reaction [Copper results in increased expression of PTGS2 mRNA]; tempol inhibits the reaction [Lead results in increased expression of PTGS2 mRNA]; tempol inhibits the reaction [Mercuric Chloride results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16987042 PMID:23415682 PMID:25596430 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
tempol inhibits the reaction [Benzene results in increased phosphorylation of RELA protein] tempol inhibits the reaction [copper histidine results in increased activity of RELA protein]; tempol inhibits the reaction [Copper results in increased activity of RELA protein] |
CTD |
PMID:16987042 PMID:30346588 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased expression of RHOA protein]] tempol inhibits the reaction [Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; tempol inhibits the reaction [Asbestos, Crocidolite results in decreased prenylation of RHOA protein]; tempol inhibits the reaction [Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; tempol inhibits the reaction [Vitamin K 3 results in decreased prenylation of RHOA protein] |
CTD |
PMID:18250367 PMID:21257924 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 mRNA]; tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 protein] |
CTD |
PMID:29609002 |
|
NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; tempol inhibits the reaction [Hydrogen Peroxide results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:17620961 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Skap2 |
src kinase associated phosphoprotein 2 |
decreases expression |
ISO |
tempol results in decreased expression of SKAP2 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
multiple interactions |
EXP |
tempol inhibits the reaction [Manganese results in increased expression of SLC12A2 protein]; tempol inhibits the reaction [Manganese results in increased oxidation of SLC12A2 protein] |
CTD |
PMID:25817889 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [Benzene results in increased expression of SOCS1 mRNA] |
CTD |
PMID:30346588 |
|
NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [Desoxycorticosterone results in decreased expression of SOD1 protein] |
CTD |
PMID:12646410 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects expression multiple interactions |
ISO EXP |
tempol affects the expression of SOD2 protein tempol affects the reaction [SOD2 protein affects the susceptibility to Acetylcholine]; tempol inhibits the reaction [Capsaicin results in decreased activity of SOD2 protein]; tempol inhibits the reaction [Capsaicin results in increased expression of SOD2 protein modified form] tempol inhibits the reaction [Isoflurane results in decreased expression of and results in decreased activity of SOD2 protein]; tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of SOD2 protein] |
CTD |
PMID:15925750 PMID:17693941 PMID:19129394 PMID:20304815 PMID:24550650 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
ISO |
tempol results in increased expression of TFRC protein |
CTD |
PMID:18073202 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
affects expression multiple interactions |
ISO EXP |
tempol affects the expression of TGFB1 protein tempol inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of TGFB1 mRNA] tempol inhibits the reaction [Aldosterone results in increased expression of TGFB1 mRNA]; tempol inhibits the reaction [Sodium Chloride results in increased expression of TGFB1 protein] |
CTD |
PMID:20232302 PMID:24550650 PMID:25204689 PMID:32726580 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP3 protein]; tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP7 protein] tempol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TNF mRNA] tempol inhibits the reaction [copper histidine results in increased expression of TNF protein]; tempol inhibits the reaction [Copper results in increased expression of TNF protein] |
CTD |
PMID:15795323 PMID:16987042 PMID:20371263 PMID:32726580 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
tempol results in increased expression of TP53 protein |
CTD |
PMID:15601469 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf3 |
Tnf receptor-associated factor 3 |
multiple interactions |
ISO |
tempol inhibits the reaction [Glucose results in increased expression of TRAF3 protein] |
CTD |
PMID:25516495 |
|
NCBI chr 6:130,199,696...130,307,168
Ensembl chr 6:130,206,484...130,305,481
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
multiple interactions |
ISO |
tempol inhibits the reaction [Arsenic Trioxide results in increased expression of TRPM4 protein] |
CTD |
PMID:31054354 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression increases expression |
EXP |
tempol results in decreased expression of UCP2 mRNA tempol results in increased expression of UCP2 protein |
CTD |
PMID:16685210 PMID:24591154 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein |
CTD |
PMID:15039284 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization |
ISO |
alvocidib results in increased localization of AIFM1 protein |
CTD |
PMID:12734434 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form |
CTD |
PMID:15039284 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Imatinib Mesylate co-treated with alvocidib] results in decreased expression of BAD protein |
CTD |
PMID:12231544 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bag1 |
BAG cochaperone 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of BAG1 mRNA; alvocidib results in decreased expression of BAG1 protein; alvocidib results in decreased expression of BAG1 protein alternative form |
CTD |
PMID:10887097 PMID:15972445 |
|
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization increases cleavage increases expression multiple interactions |
ISO |
alvocidib affects the localization of BAX protein alvocidib results in increased cleavage of BAX protein alvocidib results in increased expression of BAX protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of BAX protein; [alvocidib co-treated with gemcitabine] results in increased expression of BAX protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein; Epothilones promotes the reaction [alvocidib affects the localization of BAX protein] |
CTD |
PMID:12517783 PMID:12589031 PMID:12734434 PMID:15634644 PMID:15770523 PMID:16951203 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression decreases response to substance multiple interactions increases expression |
ISO |
alvocidib results in decreased expression of BCL2 mRNA; alvocidib results in decreased expression of BCL2 protein BCL2 protein mutant form results in decreased susceptibility to alvocidib; BCL2 protein results in decreased susceptibility to alvocidib [alvocidib co-treated with gemcitabine] results in decreased expression of BCL2 protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein]; BCL2 protein results in decreased susceptibility to [alvocidib co-treated with Epothilones] alvocidib results in increased expression of BCL2 |
CTD |
PMID:10887097 PMID:10995888 PMID:12170773 PMID:12517783 PMID:12589031 PMID:12734434 PMID:15770523 PMID:15972445 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of BCL2L1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 protein] alvocidib results in decreased expression of BCL2L1; alvocidib results in decreased expression of BCL2L1 mRNA; alvocidib results in decreased expression of BCL2L1 protein |
CTD |
PMID:12517783 PMID:15039284 PMID:15634644 PMID:16820931 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of BID protein; [alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of BID protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of BID protein] |
CTD |
PMID:11464216 PMID:12170773 PMID:12231544 PMID:15634644 PMID:16951203 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression multiple interactions |
ISO |
alvocidib results in decreased expression of BIRC3 mRNA; alvocidib results in decreased expression of BIRC3 protein Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 protein] |
CTD |
PMID:12517783 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in decreased expression of BIRC5 protein; [alvocidib co-treated with PBOX-6] results in decreased expression of BIRC5 protein; alvocidib inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of BIRC5 protein]; alvocidib results in decreased phosphorylation of and results in decreased expression of BIRC5 protein alvocidib results in decreased expression of BIRC5; alvocidib results in decreased expression of BIRC5 mRNA; alvocidib results in decreased expression of BIRC5 protein |
CTD |
PMID:12517783 PMID:12517802 PMID:16012789 PMID:16820931 PMID:20206141 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
alvocidib results in increased expression of BTG2 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Casp3 |
caspase 3 |
affects cleavage multiple interactions increases cleavage increases activity |
ISO EXP |
alvocidib affects the cleavage of CASP3 protein alvocidib inhibits the reaction [Colchicine results in increased activity of CASP3 protein] alvocidib results in increased cleavage of CASP3 protein alvocidib results in increased activity of CASP3 protein [alvocidib co-treated with 7-hydroxystaurosporine] results in increased activity of CASP3 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP3 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of CASP3 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP3 protein; [irinotecan co-treated with alvocidib] results in increased activity of CASP3 protein; alvocidib affects the cleavage of and results in increased activity of CASP3 protein; alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein]; alvocidib promotes the reaction [romidepsin results in increased activity of CASP3 protein]; alvocidib results in increased cleavage of and results in increased activity of CASP3 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:9808574 PMID:10430095 PMID:10896673 PMID:11482875 PMID:11751522 PMID:12170773 PMID:12231544 PMID:12517783 PMID:12589031 PMID:12941380 PMID:14555534 PMID:15014036 PMID:15634644 PMID:15770523 PMID:16012789 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP8 protein alvocidib results in increased cleavage of CASP8 protein |
CTD |
PMID:10896673 PMID:12231544 PMID:12589031 PMID:15634644 PMID:16012789 PMID:16951203 More...
|
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
affects cleavage increases activity multiple interactions |
ISO |
alvocidib affects the cleavage of CASP9 protein alvocidib results in increased activity of CASP9 protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP9 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein] |
CTD |
PMID:10896673 PMID:12170773 PMID:15634644 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbr3 |
carbonyl reductase 3 |
decreases expression |
ISO |
alvocidib results in decreased expression of CBR3 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
alvocidib results in decreased expression of and results in decreased activity of CCNA2 protein |
CTD |
PMID:16731754 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with PBOX-6] results in decreased expression of CCNB1 protein; alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; alvocidib results in decreased expression of and results in decreased activity of CCNB1 protein alvocidib results in decreased expression of CCNB1 protein |
CTD |
PMID:10430095 PMID:12517783 PMID:15014036 PMID:16731754 PMID:20206141 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of CCND1 protein alvocidib results in decreased expression of CCND1 protein alvocidib results in decreased activity of CCND1 protein |
CTD |
PMID:9802881 PMID:9829756 PMID:10441105 PMID:12517783 PMID:12589031 PMID:12734434 PMID:15634644 PMID:16905211 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
alvocidib results in decreased expression of CCNE1 protein |
CTD |
PMID:15014036 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with PBOX-6] results in decreased activity of CDK1 protein alvocidib results in decreased expression of CDK1 protein modified form alvocidib results in decreased activity of CDK1 protein |
CTD |
PMID:9427698 PMID:9802881 PMID:12517783 PMID:16905211 PMID:20206141 PMID:24102143 More...
|
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression decreases activity multiple interactions |
ISO |
alvocidib results in decreased expression of CDK2 protein modified form alvocidib results in decreased activity of CDK2 protein alvocidib binds to and results in decreased activity of CDK2 protein; alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein] |
CTD |
PMID:9802881 PMID:10430095 PMID:12517783 PMID:16905211 PMID:24102143 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases activity multiple interactions decreases expression |
ISO |
alvocidib results in decreased activity of CDK4 protein alvocidib binds to and results in decreased activity of CDK4 protein alvocidib results in decreased expression of CDK4 protein |
CTD |
PMID:12517783 PMID:12734434 PMID:24102143 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions |
EXP |
alvocidib inhibits the reaction [Colchicine results in increased expression of CDK5 protein] |
CTD |
PMID:12941380 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
multiple interactions |
ISO |
alvocidib binds to and results in decreased activity of CDK9 protein |
CTD |
PMID:24102143 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression increases cleavage increases expression affects expression |
ISO |
[alvocidib co-treated with gemcitabine] results in increased expression of CDKN1A protein; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A promoter]; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]; Phorbol 12,13-Dibutyrate inhibits the reaction [alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]] alvocidib results in decreased expression of CDKN1A protein alvocidib results in increased cleavage of CDKN1A protein alvocidib results in increased expression of CDKN1A protein alvocidib affects the expression of CDKN1A protein |
CTD |
PMID:10537362 PMID:12734434 PMID:15014036 PMID:15180955 PMID:15770523 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases cleavage increases expression |
ISO |
alvocidib results in increased cleavage of CDKN1B protein [alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of CDKN1B protein |
CTD |
PMID:10537362 PMID:12589031 PMID:15180955 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression multiple interactions decreases expression |
ISO |
alvocidib affects the expression of CFLAR mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alvocidib results in decreased expression of CFLAR protein] alvocidib results in decreased expression of CFLAR; alvocidib results in decreased expression of CFLAR protein |
CTD |
PMID:16820931 PMID:16951203 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein |
CTD |
PMID:15039284 |
|
NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
alvocidib affects the localization of CYCS protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of CYCS protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein] |
CTD |
PMID:12170773 PMID:12517783 PMID:15634644 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization multiple interactions |
ISO |
alvocidib affects the localization of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of DIABLO protein; [Imatinib Mesylate co-treated with alvocidib] results in increased secretion of DIABLO protein |
CTD |
PMID:12231544 PMID:12517783 PMID:15039284 PMID:15634644 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression increases response to substance decreases expression |
ISO |
alvocidib results in increased expression of E2F1 protein E2F1 results in increased susceptibility to alvocidib alvocidib results in decreased expression of E2F1 mRNA |
CTD |
PMID:12533675 PMID:21239698 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
H2ax |
H2A.X variant histone |
affects expression |
ISO |
alvocidib affects the expression of H2AX protein |
CTD |
PMID:15078984 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of HMGA1 mRNA |
CTD |
PMID:21239698 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
alvocidib affects the localization of HTRA2 protein |
CTD |
PMID:12517783 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] |
CTD |
PMID:23589332 |
|
NCBI chr 5:103,020,969...103,021,523
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] |
CTD |
PMID:23589332 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Imatinib Mesylate co-treated with alvocidib] results in increased activity of JUN protein |
CTD |
PMID:12231544 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression decreases phosphorylation |
ISO |
alvocidib results in decreased expression of KIT mRNA; alvocidib results in decreased expression of KIT promoter alvocidib results in decreased phosphorylation of KIT protein |
CTD |
PMID:16740725 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein |
CTD |
PMID:15039284 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein] |
CTD |
PMID:15039284 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:15014036 PMID:15039284 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK14 protein |
CTD |
PMID:15634644 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:15014036 PMID:15039284 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK8 protein; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:15039284 PMID:15634644 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression decreases response to substance decreases expression multiple interactions |
ISO |
alvocidib affects the expression of MCL1 mRNA; alvocidib affects the expression of MCL1 protein MCL1 results in decreased susceptibility to alvocidib alvocidib results in decreased expression of MCL1 mRNA; alvocidib results in decreased expression of MCL1 protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of MCL1 protein; [Imatinib Mesylate co-treated with alvocidib] results in decreased expression of MCL1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 protein] |
CTD |
PMID:10887097 PMID:12231544 PMID:12429644 PMID:12517783 PMID:12533675 PMID:15634644 PMID:15972445 More...
|
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases expression |
ISO |
alvocidib results in decreased expression of MDM2 mRNA; alvocidib results in decreased expression of MDM2 protein |
CTD |
PMID:12589031 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mx1 |
MX dynamin like GTPase 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
|
|
G |
Nelfa |
negative elongation factor complex member A |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr14:76,808,920...76,832,998
Ensembl chr14:76,808,870...76,832,994
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression multiple interactions |
ISO |
alvocidib results in increased expression of NFKBIA protein modified form alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form] |
CTD |
PMID:15039284 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of PARP1 protein; [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of PARP1 protein; [alvocidib co-treated with gemcitabine] results in increased cleavage of PARP1 protein; alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein] |
CTD |
PMID:10430095 PMID:12170773 PMID:12517783 PMID:15039284 PMID:15634644 PMID:15770523 PMID:15972445 PMID:16012789 PMID:20663931 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
multiple interactions |
EXP |
alvocidib inhibits the reaction [Colchicine results in increased expression of PAWR protein] |
CTD |
PMID:12941380 |
|
NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases activity |
ISO |
alvocidib results in decreased activity of PCNA protein |
CTD |
PMID:10441105 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
alvocidib results in increased expression of PERP mRNA |
CTD |
PMID:21382384 |
|
NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511
|
|
G |
Polr2a |
RNA polymerase II subunit A |
decreases expression decreases phosphorylation multiple interactions |
ISO |
alvocidib results in decreased expression of POLR2A mRNA alvocidib results in decreased phosphorylation of POLR2A protein alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]] Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein] |
CTD |
PMID:15039284 PMID:21239698 PMID:23589332 PMID:24102143 |
|
NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455
|
|
G |
Pygb |
glycogen phosphorylase B |
affects binding |
ISO |
PYGB protein binds to alvocidib |
CTD |
PMID:11368340 |
|
NCBI chr 3:139,611,724...139,658,521
Ensembl chr 3:139,611,749...139,663,553
|
|
G |
Pygl |
glycogen phosphorylase L |
affects binding |
ISO |
PYGL protein binds to alvocidib |
CTD |
PMID:11368340 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases activity decreases response to substance multiple interactions decreases phosphorylation decreases expression |
ISO |
alvocidib results in decreased activity of RB1 protein modified form RB1 results in decreased susceptibility to alvocidib [docetaxel co-treated with alvocidib] results in decreased phosphorylation of and results in decreased expression of RB1 protein alvocidib results in decreased phosphorylation of RB1 protein alvocidib results in decreased expression of RB1 protein; alvocidib results in decreased expression of RB1 protein modified form |
CTD |
PMID:9829756 PMID:10441105 PMID:15180955 PMID:15297405 PMID:16905211 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of RBL1 protein |
CTD |
PMID:9829756 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein alvocidib results in decreased expression of STAT3 mRNA |
CTD |
PMID:15039284 PMID:21239698 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Supt5h |
SPT5 homolog, DSIF elongation factor subunit |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr 1:83,586,713...83,616,971
Ensembl chr 1:83,586,718...83,616,892
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases activity |
ISO |
alvocidib analog results in decreased activity of TGFB1 protein |
CTD |
PMID:31652400 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21204955 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
alvocidib results in increased expression of TNFRSF10A |
CTD |
PMID:16820931 |
|
NCBI chr15:44,839,818...44,867,582
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases response to substance increases expression |
ISO |
[alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein alvocidib results in increased susceptibility to TNFSF10 alvocidib results in increased expression of TNFSF10 |
CTD |
PMID:16820931 PMID:16951203 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression multiple interactions increases expression |
ISO |
alvocidib results in decreased expression of TP53 protein [docetaxel co-treated with alvocidib] results in increased expression of TP53 protein [alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of TP53 protein |
CTD |
PMID:9808574 PMID:10537362 PMID:12589031 PMID:15180955 PMID:15297405 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
alvocidib results in decreased expression of VEGFA mRNA |
CTD |
PMID:21239698 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression multiple interactions |
ISO |
alvocidib results in decreased expression of XIAP mRNA; alvocidib results in decreased expression of XIAP protein [irinotecan co-treated with alvocidib] results in increased cleavage of XIAP protein; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP protein] |
CTD |
PMID:10887097 PMID:11751522 PMID:12517783 PMID:15385934 PMID:15972445 PMID:16951203 More...
|
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance |
ISO |
1-Deoxynojirimycin results in decreased susceptibility to APP protein |
CTD |
PMID:19028522 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased activity of CASP3 protein] |
CTD |
PMID:19028522 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of CD36 mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of CEBPA mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein] |
CTD |
PMID:19028522 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of FASN mRNA] |
CTD |
PMID:25445511 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of FBP2 protein] |
CTD |
PMID:25446853 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of G6PC protein] |
CTD |
PMID:25446853 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gck |
glucokinase |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GCK protein] |
CTD |
PMID:25446853 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
1-Deoxynojirimycin inhibits the reaction [Dietary Fats results in increased expression of GPT protein] |
CTD |
PMID:25445511 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of INSR protein] |
CTD |
PMID:25446853 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of LPL mRNA] |
CTD |
PMID:25446853 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Pc |
pyruvate carboxylase |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCX protein] |
CTD |
PMID:25446853 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCK1 protein] |
CTD |
PMID:25446853 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] results in increased expression of PDHA1 mRNA |
CTD |
PMID:25446853 |
|
NCBI chr X:34,700,481...34,714,309
Ensembl chr X:34,700,409...34,714,311
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PDK1 mRNA] |
CTD |
PMID:25446853 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pfkp |
phosphofructokinase, platelet |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PFKP protein] |
CTD |
PMID:25446853 |
|
NCBI chr17:63,729,743...63,794,021
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PKLR protein] |
CTD |
PMID:25446853 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
multiple interactions |
ISO |
[1-Deoxynojirimycin co-treated with Dietary Fats] results in increased expression of PPARGC1B mRNA |
CTD |
PMID:25445511 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity decreases expression |
ISO |
Haloperidol inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased activity of ABCB1 protein Haloperidol results in decreased expression of ABCB1 mRNA |
CTD |
PMID:15946544 PMID:16810505 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases expression |
ISO |
Haloperidol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of ABCC1 mRNA |
CTD |
PMID:15946544 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Haloperidol inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
decreases expression |
ISO |
Haloperidol results in decreased expression of ACADVL protein |
CTD |
PMID:34122009 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ACAT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ACSL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:80,140,996...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Adam1a |
ADAM metallopeptidase domain 1a |
decreases expression |
EXP |
Haloperidol results in decreased expression of ADAM1A mRNA |
CTD |
PMID:16715494 |
|
NCBI chr12:35,017,433...35,020,300
Ensembl chr12:35,017,315...35,020,311
|
|
G |
Adcy5 |
adenylate cyclase 5 |
affects response to substance multiple interactions |
ISO |
ADCY5 protein affects the susceptibility to Haloperidol SCH 23390 inhibits the reaction [ADCY5 protein affects the susceptibility to Haloperidol] |
CTD |
PMID:12223546 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
ISO |
Haloperidol affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adora2a |
adenosine A2a receptor |
affects response to substance |
ISO |
ADORA2A protein affects the susceptibility to Haloperidol |
CTD |
PMID:11172060 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adsl |
adenylosuccinate lyase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ADSL protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of AGPAT1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:4,135,955...4,144,880
Ensembl chr20:4,135,957...4,145,278
|
|
G |
Agps |
alkylglycerone phosphate synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of AGPS protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:60,747,323...60,845,831
Ensembl chr 3:60,747,323...60,845,830
|
|
G |
Ak4 |
adenylate kinase 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of AK4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AKT1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases expression |
EXP |
Haloperidol results in increased expression of AKT2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ALDH18A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:239,375,657...239,407,967
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOC mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Ankhd1 |
ankyrin repeat and KH domain containing 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ANKHD1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Ap2a2 |
adaptor related protein complex 2 subunit alpha 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AP2A2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:196,652,315...196,725,609
Ensembl chr 1:196,652,337...196,725,603
|
|
G |
Ap2b1 |
adaptor related protein complex 2 subunit beta 1 |
affects expression |
EXP |
Haloperidol affects the expression of AP2B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:68,099,397...68,205,023
Ensembl chr10:68,099,547...68,205,013
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
increases expression |
ISO |
Haloperidol results in increased expression of AP2M1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140
|
|
G |
Ap3b1 |
adaptor related protein complex 3 subunit beta 1 |
increases expression |
ISO |
Haloperidol results in increased expression of AP3B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:25,600,069...25,800,937
Ensembl chr 2:25,600,040...25,800,935
|
|
G |
Apod |
apolipoprotein D |
increases expression |
ISO |
Haloperidol results in increased expression of APOD mRNA |
CTD |
PMID:14647396 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of APPL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ARC mRNA 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of ARC mRNA] |
CTD |
PMID:18208916 PMID:19695244 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:43,997,983...44,014,543
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Arf3 |
ADP-ribosylation factor 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
|
|
G |
Arl3 |
ADP ribosylation factor like GTPase 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820
|
|
G |
Arl5a |
ADP-ribosylation factor like GTPase 5A |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL5A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
increases expression |
ISO |
Haloperidol results in increased expression of ARPC4 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Haloperidol results in decreased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
Haloperidol results in increased expression of ASPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:22,603,879...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1B2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of ATP2A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp6v1b1 |
ATPase H+ transporting V1 subunit B1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ATP6V1B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ATP6V1B2 mRNA |
CTD |
PMID:16465460 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AXIN2 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of BAX protein Haloperidol results in increased expression of BAX mRNA; Haloperidol results in increased expression of BAX protein |
CTD |
PMID:16462815 PMID:17069804 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat2 |
branched chain amino acid transaminase 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of BCAT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:96,040,407...96,060,008
Ensembl chr 1:96,042,625...96,060,007
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Haloperidol results in increased expression of BCL2 protein |
CTD |
PMID:17069804 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression increases expression |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein] Haloperidol results in increased expression of BCL2L1 protein |
CTD |
PMID:16462815 PMID:17805306 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions decreases expression increases expression |
EXP ISO |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; Haloperidol inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] Haloperidol results in decreased expression of BDNF mRNA; Haloperidol results in decreased expression of BDNF protein Haloperidol inhibits the reaction [Cocaine results in decreased expression of BDNF protein] Haloperidol results in increased expression of BDNF protein Haloperidol results in increased expression of BDNF mRNA |
CTD |
PMID:11488957 PMID:12393228 PMID:12478621 PMID:15168214 PMID:17442543 PMID:17805306 PMID:18208916 PMID:20554863 PMID:29182611 More...
|
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
affects expression |
EXP |
Haloperidol affects the expression of BET1L mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:195,930,165...195,935,072
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bop1 |
BOP1 ribosomal biogenesis factor |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of BOP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:108,172,062...108,195,875
Ensembl chr 7:108,172,066...108,195,931
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
decreases expression |
ISO |
Haloperidol results in decreased expression of BPTF mRNA |
CTD |
PMID:14647396 |
|
NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
decreases expression |
EXP ISO |
Haloperidol results in decreased expression of CACNA1A mRNA |
CTD |
PMID:14647396 PMID:16715494 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
affects activity |
EXP |
Haloperidol affects the activity of CALCA protein |
CTD |
PMID:10075105 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Haloperidol results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of and results in decreased phosphorylation of CAMK2A protein Haloperidol results in decreased expression of CAMK2A protein Haloperidol results in increased expression of CAMK2A mRNA |
CTD |
PMID:15860345 PMID:18061412 PMID:19289156 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2D mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of CAMK4 protein Haloperidol results in increased expression of CAMK4 mRNA |
CTD |
PMID:15860345 PMID:19289156 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression |
EXP |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:15168214 PMID:17805306 PMID:18590723 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases activity decreases expression |
EXP ISO |
Carvedilol inhibits the reaction [Haloperidol results in decreased expression of CAT protein]; Haloperidol results in decreased activity of and results in decreased expression of CAT protein; Zolpidem inhibits the reaction [Haloperidol results in decreased activity of CAT] Cannabidiol inhibits the reaction [Haloperidol results in decreased activity of CAT protein] |
CTD |
PMID:12010767 PMID:12482469 PMID:16564057 PMID:17513028 PMID:30217539 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbx5 |
chromobox 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CBX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Ccdc121rt |
coiled-coil domain containing 121, retrotransposed |
increases expression |
ISO |
Haloperidol results in increased expression of CCDC121 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:93,253,752...93,255,406
Ensembl chr13:93,254,387...93,255,358
|
|
G |
Cck |
cholecystokinin |
increases expression |
EXP |
Haloperidol results in increased expression of CCK mRNA |
CTD |
PMID:10974607 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CCND1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Haloperidol results in increased expression of CCND3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccnl1 |
cyclin L1 |
increases expression |
EXP |
Haloperidol results in increased expression of CCNL1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CCT8 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
EXP |
Haloperidol results in increased expression of CDC42 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cfap161 |
cilia and flagella associated protein 161 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CFAP161 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:137,743,783...137,768,685
Ensembl chr 1:137,743,784...137,768,730
|
|
G |
Cfdp1 |
craniofacial development protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CFDP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:39,718,313...39,823,819
Ensembl chr19:39,718,347...39,823,824
|
|
G |
Cfl1 |
cofilin 1 |
increases expression |
ISO |
Haloperidol results in increased expression of CFL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chl1 |
cell adhesion molecule L1-like |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHL1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:136,291,504...136,505,830
Ensembl chr 4:136,291,463...136,503,265
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHN1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:58,509,822...58,676,774
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
Haloperidol results in increased expression of CHORDC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects response to substance |
ISO |
CHRM4 affects the susceptibility to Haloperidol |
CTD |
PMID:21269601 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Cldn11 |
claudin 11 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CLDN11 mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Clta |
clathrin, light chain A |
affects expression |
EXP |
Haloperidol affects the expression of CLTA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Cltb |
clathrin, light chain B |
decreases expression |
EXP |
Haloperidol results in decreased expression of CLTB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:10,001,512...10,019,201
Ensembl chr17:10,001,513...10,019,169
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CMYA5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:24,279,520...24,378,253
Ensembl chr 2:24,279,528...24,378,364
|
|
G |
Cnot3 |
CCR4-NOT transcription complex, subunit 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CNOT3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,555,924...65,572,167
Ensembl chr 1:65,555,924...65,572,167
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases expression |
ISO |
Haloperidol results in decreased expression of CNP mRNA |
CTD |
PMID:17177202 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases methylation |
ISO EXP |
CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]] Haloperidol inhibits the reaction [Methylazoxymethanol Acetate results in decreased methylation of CNR1 promoter] Haloperidol results in increased methylation of CNR1 promoter |
CTD |
PMID:28017790 PMID:30496751 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Coil |
coilin |
increases expression |
EXP |
Haloperidol results in increased expression of COIL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:73,789,077...73,810,378
Ensembl chr10:73,789,488...73,810,393
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of COPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of COPS4 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887
|
|
G |
Cpn1 |
carboxypeptidase N subunit 1 |
increases expression |
EXP |
Haloperidol results in increased expression of CPN1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:242,844,575...242,873,465
Ensembl chr 1:242,844,212...242,873,465
|
|
G |
Cpne3 |
copine 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CPNE3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:33,014,658...33,064,004
Ensembl chr 5:33,016,307...33,063,934
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of CREB1 protein] Haloperidol results in increased activity of CREB1 protein modified form Amphetamine affects the reaction [Haloperidol results in increased activity of CREB1 protein modified form] |
CTD |
PMID:12125044 PMID:12871586 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
EXP |
Haloperidol results in decreased expression of CRHBP mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:26,692,403...26,704,710
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRY1 mRNA |
CTD |
PMID:27746588 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CSNK2A1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Haloperidol results in increased expression of CST3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctnna1 |
catenin alpha 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CTNNA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression multiple interactions increases expression |
ISO EXP |
Haloperidol results in decreased expression of CTNNB1 mRNA DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 PMID:18797397 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctrl |
chymotrypsin-like |
increases expression |
EXP |
Haloperidol results in increased expression of CTRL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr19:33,827,279...33,829,129
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Ctsk |
cathepsin K |
increases expression |
EXP |
Haloperidol results in increased expression of CTSK mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CYB5R1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 protein polymorphism affects the susceptibility to Haloperidol |
CTD |
PMID:15538130 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dcaf6 |
DDB1 and CUL4 associated factor 6 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DCAF6 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr13:77,626,257...77,727,645
Ensembl chr13:77,626,307...77,727,512
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
ISO EXP |
Haloperidol results in increased expression of DCLK1 mRNA |
CTD |
PMID:15860345 PMID:18797397 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
increases expression |
ISO |
Haloperidol results in increased expression of DDX27 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372
|
|
G |
Ddx46 |
DEAD-box helicase 46 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of DDX46 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:8,944,197...8,988,476
Ensembl chr17:8,944,454...8,988,439
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DDX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283
|
|
G |
Dennd10 |
DENN domain containing 10 |
increases expression |
EXP |
Haloperidol results in increased expression of DENND10 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:259,950,928...259,974,456
Ensembl chr 1:259,950,866...259,974,455
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
increases expression |
ISO |
Haloperidol results in increased expression of DEPP1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of DGKA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Dhx36 |
DEAH-box helicase 36 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DHX36 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:146,856,469...146,894,577
Ensembl chr 2:146,856,469...146,894,572
|
|
G |
Dhx38 |
DEAH-box helicase 38 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DHX38 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:37,512,891...37,530,140
Ensembl chr19:37,512,891...37,530,140
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
decreases expression |
EXP |
Haloperidol results in decreased expression of DLAT mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
increases expression |
ISO |
Haloperidol results in increased expression of DLG2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
|
|
G |
Dnah1 |
dynein, axonemal, heavy chain 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of DNAH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:6,455,514...6,517,103
Ensembl chr16:6,456,002...6,518,350
|
|
G |
Dnah3 |
dynein, axonemal, heavy chain 3 |
increases expression |
ISO |
Haloperidol results in increased expression of DNAH3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:174,305,929...174,479,490
Ensembl chr 1:174,306,644...174,479,474
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of DNAJB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of DNAJB11 protein Haloperidol results in increased expression of DNAJB11 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dpf1 |
double PHD fingers 1 |
increases expression |
ISO |
Haloperidol results in increased expression of DPF1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dr1 |
down-regulator of transcription 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:1,458,223...1,469,578
Ensembl chr14:1,458,223...1,469,638
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding affects activity decreases expression increases expression |
ISO EXP |
Haloperidol binds to DRD1 protein Haloperidol affects the activity of DRD1 protein Haloperidol results in decreased expression of DRD1 mRNA Haloperidol results in increased expression of DRD1 protein |
CTD |
PMID:8750706 PMID:8794996 PMID:12887421 PMID:16983399 PMID:23611293 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding increases expression multiple interactions affects response to substance affects activity |
ISO EXP |
DRD2 protein binds to Haloperidol; DRD2 protein binds to Haloperidol analog; Haloperidol binds to DRD2 protein Haloperidol results in increased expression of DRD2 mRNA; Haloperidol results in increased expression of DRD2 protein Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 mRNA]; Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 protein] DRD2 affects the susceptibility to Haloperidol; DRD2 protein affects the susceptibility to Haloperidol [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Ethanol; [Haloperidol results in increased expression of DRD2 protein] which results in decreased susceptibility to Pentobarbital; Haloperidol binds to and results in decreased activity of DRD2 protein Haloperidol binds to DRD2; Haloperidol binds to DRD2 protein; Haloperidol binds to DRD2 protein alternative form Haloperidol results in increased expression of DRD2; Haloperidol results in increased expression of DRD2 mRNA; Haloperidol results in increased expression of DRD2 protein [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; cyclo(leucylglycine) inhibits the reaction [Haloperidol results in increased expression of DRD2 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3B protein]; felbamate inhibits the reaction [Haloperidol affects the activity of DRD2 protein]; Haloperidol binds to and results in decreased activity of DRD2 protein; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol inhibits the reaction [iodosulpride binds to DRD2 protein]; Haloperidol inhibits the reaction [Spiperone binds to DRD2 protein]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; zinc chloride inhibits the reaction [Haloperidol binds to DRD2 protein] |
CTD |
PMID:1351265 PMID:1361536 PMID:1380082 PMID:2945998 PMID:7845605 PMID:7878047 PMID:8115415 PMID:8200438 PMID:8794996 PMID:9109525 PMID:9808703 PMID:10720636 PMID:10936494 PMID:11172060 PMID:11927170 PMID:11997696 PMID:12191584 PMID:12476322 PMID:14552778 PMID:15716360 PMID:16033416 PMID:16144542 PMID:18295747 PMID:19120057 PMID:20361897 PMID:20730801 PMID:23611293 More...
|
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
affects binding multiple interactions |
ISO EXP |
DRD3 protein binds to Haloperidol analog Haloperidol affects the reaction [Methylazoxymethanol Acetate results in increased expression of DRD3 mRNA] |
CTD |
PMID:14552778 PMID:32360362 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Drd4 |
dopamine receptor D4 |
affects activity affects binding |
ISO EXP |
Haloperidol affects the activity of DRD4 protein Haloperidol binds to Drd4 protein |
CTD RGD |
PMID:23611293 PMID:8078498 |
RGD:7248459 |
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Drp2 |
dystrophin related protein 2 |
increases expression |
EXP |
Haloperidol results in increased expression of DRP2 mRNA alternative form |
CTD |
PMID:16715494 |
|
NCBI chr X:97,607,577...97,658,115
Ensembl chr X:97,607,719...97,655,684
|
|
G |
Dtnbp1 |
dystrobrevin binding protein 1 |
increases response to substance affects response to substance |
ISO |
DTNBP1 gene polymorphism results in increased susceptibility to Haloperidol DTNBP1 protein affects the susceptibility to Haloperidol |
CTD |
PMID:19369910 |
|
NCBI chr17:19,685,218...19,776,668
Ensembl chr17:19,685,215...19,776,661
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of EEF1G protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Egr1 |
early growth response 1 |
affects expression increases expression multiple interactions |
EXP ISO |
Haloperidol affects the expression of EGR1 protein Haloperidol results in increased expression of EGR1 mRNA; Haloperidol results in increased expression of EGR1 protein Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]; OPRM1 protein inhibits the reaction [Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]] |
CTD |
PMID:12243769 PMID:16452686 PMID:17028028 PMID:17913375 PMID:18208916 PMID:19695244 PMID:20184921 More...
|
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
affects expression decreases expression increases expression |
ISO EXP |
Haloperidol affects the expression of EGR2 mRNA Haloperidol results in decreased expression of EGR2 protein Haloperidol results in increased expression of EGR2 mRNA |
CTD |
PMID:17028028 PMID:18208916 PMID:19401217 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eif2b5 |
eukaryotic translation initiation factor 2B subunit epsilon |
increases expression |
ISO |
Haloperidol results in increased expression of EIF2B5 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:80,394,433...80,404,468
Ensembl chr11:80,394,433...80,404,419
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of EIF5A protein |
CTD |
PMID:34122009 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases phosphorylation multiple interactions |
ISO EXP |
Haloperidol results in increased phosphorylation of ELK1 protein SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] Nifedipine affects the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:12871586 PMID:17913375 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Eno1 |
enolase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ENO1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:17805306 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ERAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Haloperidol results in increased expression of and results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:26961615 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ERBB4 protein Haloperidol results in increased expression of and results in increased phosphorylation of ERBB4 protein |
CTD |
PMID:18184445 PMID:26961615 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ergic1 |
endoplasmic reticulum-golgi intermediate compartment 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of ERGIC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:16,531,192...16,627,183
Ensembl chr10:16,531,194...16,626,957
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
Haloperidol results in decreased expression of EZR protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
affects response to substance increases expression |
ISO |
FABP3 affects the susceptibility to Haloperidol Haloperidol results in increased expression of FABP3 protein |
CTD |
PMID:20181611 PMID:34122009 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Haloperidol results in increased expression of FASN mRNA |
CTD |
PMID:16027736 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of FLT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Haloperidol results in increased expression of FNDC4 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression increases expression |
ISO EXP |
8-Hydroxy-2-(di-n-propylamino)tetralin affects the reaction [Haloperidol results in increased expression of FOS protein]; Dizocilpine Maleate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; ifenprodil inhibits the reaction [Haloperidol results in increased expression of FOS protein]; tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]; traxoprodil mesylate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; WAY 100135 inhibits the reaction [tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]] 8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; Clozapine affects the reaction [Haloperidol results in increased expression of FOS protein]; Dronabinol promotes the reaction [Haloperidol results in increased expression of FOS protein]; Nifedipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Nimodipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Propranolol inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Scopolamine inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Theophylline inhibits the reaction [Haloperidol results in increased expression of FOS mRNA] Haloperidol results in decreased expression of FOS mRNA; Haloperidol results in decreased expression of FOS protein Haloperidol results in increased expression of FOS mRNA; Haloperidol results in increased expression of FOS protein |
CTD |
PMID:1393566 PMID:9571656 PMID:9748542 PMID:10199625 PMID:10435392 PMID:11166331 PMID:11409749 PMID:11440804 PMID:11516571 PMID:11602683 PMID:11997696 PMID:12093589 PMID:12125044 PMID:12243769 PMID:12464447 PMID:15120589 PMID:15140647 PMID:17028028 PMID:17913375 PMID:18208916 PMID:18295747 PMID:18521575 PMID:18585397 PMID:18789920 PMID:19352073 PMID:19695244 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
Haloperidol results in increased expression of FOSB protein alternative form 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOSB mRNA] Haloperidol results in increased expression of FOSB modified form; Haloperidol results in increased expression of FOSB mRNA; Haloperidol results in increased expression of FOSB protein |
CTD |
PMID:8714707 PMID:11180499 PMID:12243769 PMID:15579174 PMID:19695244 PMID:24067299 More...
|
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Amphetamine affects the reaction [Haloperidol results in increased expression of FOSL1 protein] Haloperidol results in increased expression of FOSL1 mRNA; Haloperidol results in increased expression of FOSL1 protein |
CTD |
PMID:12125044 PMID:18208916 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
EXP |
Haloperidol results in increased expression of FOSL2 mRNA |
CTD |
PMID:12243769 |
|
NCBI chr 6:24,297,898...24,319,157
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions affects response to substance increases phosphorylation |
ISO |
FYN gene mutant form inhibits the reaction [Haloperidol results in increased phosphorylation of GRIN2B protein] FYN protein affects the susceptibility to Haloperidol Haloperidol results in increased phosphorylation of FYN protein |
CTD |
PMID:16407246 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of GABRA1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of GABRB3 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions decreases expression increases expression |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein Haloperidol results in decreased expression of GAD1 mRNA; Haloperidol results in decreased expression of GAD1 protein Haloperidol results in increased expression of GAD1 mRNA |
CTD |
PMID:12887421 PMID:14519413 PMID:15061247 PMID:15967061 PMID:18923069 PMID:19359144 More...
|
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of GAD2 mRNA; Haloperidol results in decreased expression of GAD2 protein Haloperidol results in increased expression of GAD2 mRNA |
CTD |
PMID:18923069 PMID:19359144 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GALNT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
EXP |
Haloperidol results in increased expression of GAPDH mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gda |
guanine deaminase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of GDA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Haloperidol results in increased expression of GDPD3 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of GFAP protein |
CTD |
PMID:34122009 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gimap5 |
GTPase, IMAP family member 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GIMAP5 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 4:77,693,417...77,701,025
Ensembl chr 4:77,687,564...77,703,086
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GJA1 protein |
CTD |
PMID:18585900 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GLO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
Haloperidol results in decreased expression of GLUL mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:65,969,064...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gna12 |
G protein subunit alpha 12 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNA12 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:16,813,941...16,898,111
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GNAO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:11,034,874...11,192,502
Ensembl chr19:11,035,956...11,192,493
|
|
G |
Gnas |
GNAS complex locus |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAS mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [manganese chloride results in increased secretion of GNRH1 protein] |
CTD |
PMID:18603625 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
affects expression multiple interactions |
EXP ISO |
Haloperidol affects the expression of GOT2 mRNA [Cuprizone co-treated with Haloperidol] results in increased expression of GOT2 protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of GPX1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIA1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
increases expression |
EXP |
Haloperidol results in increased expression of GRIK2 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
increases expression |
EXP |
Haloperidol results in increased expression of GRIK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
increases expression |
ISO EXP |
Haloperidol results in increased expression of GRIK5 mRNA |
CTD |
PMID:14647396 PMID:15860345 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of GRIN1 mRNA Haloperidol results in increased expression of GRIN1 mRNA |
CTD |
PMID:12020038 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIN2A mRNA; Haloperidol results in decreased expression of GRIN2A protein |
CTD |
PMID:12608697 PMID:15860345 PMID:18061412 |
|
NCBI chr10:5,630,684...6,043,341
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions increases phosphorylation |
ISO |
FYN gene mutant form inhibits the reaction [Haloperidol results in increased phosphorylation of GRIN2B protein] |
CTD |
PMID:16407246 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
increases expression |
EXP |
Haloperidol results in increased expression of GRIN2C mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIN2D mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Grin3b |
glutamate ionotropic receptor NMDA type subunit 3B |
increases expression |
EXP |
Haloperidol results in increased expression of GRIN3B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:9,730,861...9,737,183
Ensembl chr 7:9,730,862...9,737,183
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRK6 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr17:9,177,018...9,192,644
Ensembl chr17:9,177,019...9,192,644
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
increases expression |
EXP |
Haloperidol results in increased expression of GRM1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
|
|
G |
Grm2 |
glutamate metabotropic receptor 2 |
increases expression |
EXP |
Haloperidol results in increased expression of GRM2 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 8:107,280,099...107,293,159
Ensembl chr 8:107,280,099...107,293,146
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of GSK3A protein DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3A protein] |
CTD |
PMID:16144542 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3B protein] Haloperidol results in increased expression of GSK3B mRNA; Haloperidol results in increased expression of GSK3B protein |
CTD |
PMID:16144542 PMID:19359144 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
EXP |
Haloperidol results in increased expression of GSTM1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GSTM2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases expression |
ISO |
Haloperidol inhibits the reaction [GSTP1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of GSTP1 mRNA |
CTD |
PMID:15946544 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gtf2e1 |
general transcription factor IIE subunit 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of GTF2E1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:63,182,073...63,215,349
Ensembl chr11:63,182,349...63,213,942
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of HADHB protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Hars1 |
histidyl-tRNA synthetase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of HARS protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,381,649...28,398,699
Ensembl chr18:28,381,655...28,398,740
|
|
G |
Hcfc1 |
host cell factor C1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of HCFC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:151,687,779...151,712,688
Ensembl chr X:151,687,779...151,712,638
|
|
G |
Higd1a |
HIG1 hypoxia inducible domain family, member 1A |
increases expression |
ISO |
Haloperidol results in increased expression of HIGD1A mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:121,514,152...121,523,382
Ensembl chr 8:121,514,156...121,523,443
|
|
G |
Hist2h2aa2 |
histone cluster 2 H2A family member A2 |
increases expression |
ISO |
Haloperidol results in increased expression of H2AC18 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:183,801,369...183,801,987
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases activity multiple interactions increases expression |
ISO |
Haloperidol results in increased activity of HMGCR protein [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Triglycerides Haloperidol results in increased expression of HMGCR mRNA |
CTD |
PMID:16027736 PMID:17052361 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of HMGCS1 mRNA |
CTD |
PMID:16027736 PMID:17052361 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of HNRNPC protein |
CTD |
PMID:34122009 |
|
NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression |
ISO |
Haloperidol results in decreased expression of HNRNPK protein |
CTD |
PMID:34122009 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions increases expression |
EXP |
Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA] |
CTD |
PMID:12464447 PMID:15860345 PMID:20147574 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Hpcal4 |
hippocalcin-like 4 |
decreases expression |
EXP |
Haloperidol results in decreased expression of HPCAL4 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 5:135,454,477...135,466,417
Ensembl chr 5:135,454,540...135,466,416
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of HSD17B4 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hspg2 |
heparan sulfate proteoglycan 2 |
decreases expression multiple interactions |
ISO |
Haloperidol results in decreased expression of HSPG2 mRNA HSPG2 gene results in increased susceptibility to [Haloperidol co-treated with Reserpine] |
CTD |
PMID:20072119 |
|
NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of HSPH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Htr1d |
5-hydroxytryptamine receptor 1D |
decreases expression |
EXP |
Haloperidol results in decreased expression of HTR1D mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 5:148,655,979...148,676,534
Ensembl chr 5:148,674,495...148,675,619
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects binding multiple interactions |
EXP ISO |
Haloperidol binds to HTR2A protein [Phencyclidine co-treated with Haloperidol] affects the activity of HTR2A protein |
CTD |
PMID:7520908 PMID:12191584 PMID:15380371 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
decreases expression |
EXP |
Haloperidol results in decreased expression of HTR2C mRNA |
CTD |
PMID:17868938 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of ID2 mRNA Haloperidol results in increased expression of ID2 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ikbip |
IKBKB interacting protein |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of IKBIP protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:25,579,759...25,598,548
Ensembl chr 7:25,579,832...25,605,162
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Cannabidiol co-treated with Haloperidol] results in increased expression of IL10 protein |
CTD |
PMID:30217539 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [Haloperidol results in increased expression of IL1B protein] |
CTD |
PMID:30217539 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Haloperidol results in increased expression of IL6 mRNA Cannabidiol inhibits the reaction [Haloperidol results in increased expression of IL6 mRNA] |
CTD |
PMID:30217539 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilkap |
ILK associated serine/threonine phosphatase |
decreases expression |
EXP |
Haloperidol results in decreased expression of ILKAP mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:91,966,440...91,988,791
Ensembl chr 9:91,966,441...91,988,892
|
|
G |
Impdh1 |
inosine monophosphate dehydrogenase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of IMPDH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:57,801,842...57,817,434
Ensembl chr 4:57,801,831...57,819,076
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of INHA mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Haloperidol results in increased expression of INHBE mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression decreases expression |
EXP |
Haloperidol results in increased expression of JUN mRNA; Haloperidol results in increased expression of JUN protein Haloperidol results in decreased expression of JUN mRNA |
CTD |
PMID:12093589 PMID:12125044 PMID:15860345 PMID:18208916 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression increases expression |
EXP |
8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of JUNB mRNA] Haloperidol results in decreased expression of JUNB mRNA |
CTD |
PMID:12093589 PMID:19695244 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
increases expression |
ISO |
Haloperidol results in increased expression of KCNA1 mRNA; Haloperidol results in increased expression of KCNA1 protein |
CTD |
PMID:18797397 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcnab1 |
potassium voltage-gated channel subfamily A regulatory beta subunit 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KCNAB1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:149,137,025...149,603,540
Ensembl chr 2:149,137,041...149,603,534
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Haloperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Haloperidol results in decreased activity of KCNH2 protein |
CTD |
PMID:15671647 PMID:16278312 PMID:16494862 PMID:19583963 PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnip3 |
potassium voltage-gated channel interacting protein 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KCNIP3 mRNA; Haloperidol results in decreased expression of KCNIP3 protein |
CTD |
PMID:18797397 |
|
NCBI chr 3:114,677,027...114,742,923
Ensembl chr 3:114,677,030...114,743,556
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of KDM1A protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression |
ISO |
Haloperidol results in increased expression of KDR protein |
CTD |
PMID:34122009 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kif5c |
kinesin family member 5C |
decreases expression |
ISO |
Haloperidol results in decreased expression of KIF5C protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Kiz |
kizuna centrosomal protein |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of KIZ protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:134,277,631...134,385,260
Ensembl chr 3:134,277,687...134,385,190
|
|
G |
Klc1 |
kinesin light chain 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KLC1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 6:130,823,416...130,866,729
Ensembl chr 6:130,823,419...130,867,031
|
|
G |
Klc4 |
kinesin light chain 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of KLC4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:14,337,164...14,351,075
Ensembl chr 9:14,337,534...14,351,066
|
|
G |
Klhdc2 |
kelch domain containing 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of KLHDC2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:87,777,183...87,791,609
Ensembl chr 6:87,777,183...87,804,187
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
decreases expression |
ISO |
Haloperidol results in decreased expression of KMT2A mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:45,116,771...45,193,320
Ensembl chr 8:45,118,814...45,193,181
|
|
G |
Kpna4 |
karyopherin subunit alpha 4 |
increases expression |
ISO |
Haloperidol results in increased expression of KPNA4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases expression |
EXP |
Haloperidol results in increased expression of KRAS mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Kremen1 |
kringle containing transmembrane protein 1 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of KREMEN1 protein Haloperidol results in increased expression of KREMEN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:80,081,870...80,147,489
Ensembl chr14:80,084,403...80,147,516
|
|
G |
Lamtor3 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 |
increases expression |
ISO |
Haloperidol results in increased expression of LAMTOR3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:226,411,389...226,423,612
Ensembl chr 2:226,411,400...226,423,607
|
|
G |
Ldhb |
lactate dehydrogenase B |
decreases expression increases expression |
ISO EXP |
Haloperidol results in decreased expression of LDHB mRNA Haloperidol results in increased expression of LDHB mRNA |
CTD |
PMID:15860345 PMID:16465460 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Haloperidol results in increased expression of LDLR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of LGALS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lipa |
lipase A, lysosomal acid type |
increases expression |
ISO |
Haloperidol results in increased expression of LIPA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:232,024,351...232,167,329
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Mag |
myelin-associated glycoprotein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MAG mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 1:86,148,227...86,163,726
Ensembl chr 1:86,148,228...86,163,656
|
|
G |
Map1a |
microtubule-associated protein 1A |
increases expression decreases expression |
EXP ISO |
Haloperidol results in increased expression of MAP1A mRNA Haloperidol results in decreased expression of MAP1A protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAP2K1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases expression increases expression |
EXP ISO |
Haloperidol results in decreased expression of MAP2K2 mRNA Haloperidol results in increased expression of MAP2K2 mRNA |
CTD |
PMID:14647396 PMID:15860345 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP3K1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP3K12 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions decreases expression |
ISO EXP |
Haloperidol results in increased phosphorylation of MAPK1 protein [potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]; Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein] Haloperidol results in decreased expression of MAPK1 mRNA |
CTD |
PMID:12871586 PMID:15860345 PMID:28017790 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK14 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Haloperidol results in increased phosphorylation of MAPK3 protein [potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]; Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12871586 PMID:28017790 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk6 |
mitogen-activated protein kinase 6 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:76,146,650...76,169,767
Ensembl chr 8:76,146,690...76,169,720
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
EXP |
Haloperidol results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:17092607 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK9 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapre1 |
microtubule-associated protein, RP/EB family, member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of MAPRE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:142,218,846...142,246,990
Ensembl chr 3:142,212,955...142,246,983
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAS1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MBP mRNA |
CTD |
PMID:17177202 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcam |
melanoma cell adhesion molecule |
increases expression |
ISO |
Haloperidol results in increased expression of MCAM protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
|
|
G |
Mchr1 |
melanin-concentrating hormone receptor 1 |
affects binding |
ISO |
Haloperidol binds to MCHR1 protein |
CTD |
PMID:16983399 |
|
NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:112,761,554...112,764,032
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
decreases expression |
ISO |
Haloperidol results in decreased expression of MMP10 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mog |
myelin oligodendrocyte glycoprotein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MOG mRNA |
CTD |
PMID:17177202 |
|
NCBI chr20:1,513,137...1,523,473
Ensembl chr20:1,513,239...1,523,474
|
|
G |
Mrps31 |
mitochondrial ribosomal protein S31 |
increases expression |
ISO |
Haloperidol results in increased expression of MRPS31 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:69,601,349...69,621,609
Ensembl chr16:69,601,349...69,630,654
|
|
G |
Myadm |
myeloid-associated differentiation marker |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of MYADM protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,864,180...65,874,701
Ensembl chr 1:65,864,173...65,874,035
|
|
G |
Myo5b |
myosin Vb |
decreases expression |
ISO |
Haloperidol results in decreased expression of MYO5B protein |
CTD |
PMID:34122009 |
|
NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745
|
|
G |
Nap1l3 |
nucleosome assembly protein 1-like 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of NAP1L3 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:88,347,595...88,350,393
Ensembl chr X:88,347,598...88,350,393
|
|
G |
Ncan |
neurocan |
decreases expression |
ISO |
Haloperidol results in decreased expression of NCAN mRNA |
CTD |
PMID:18797397 |
|
NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
decreases expression |
ISO |
Haloperidol results in decreased expression of NCAPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:114,371,937...114,399,223
Ensembl chr 3:114,371,941...114,399,180
|
|
G |
Ncl |
nucleolin |
increases expression |
ISO |
Haloperidol results in increased expression of NCL mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136
|
|
G |
Ndufv1 |
NADH:ubiquinone oxidoreductase core subunit V1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of NDUFV1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:201,300,365...201,305,461
Ensembl chr 1:201,299,985...201,305,466
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
ISO |
Haloperidol results in decreased expression of NEDD4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of NFKB1 protein |
CTD |
PMID:16500086 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Ngfr |
nerve growth factor receptor |
decreases expression |
EXP |
Haloperidol results in decreased expression of NGFR mRNA |
CTD |
PMID:16513140 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nifk |
nucleolar protein interacting with the FHA domain of MKI67 |
decreases expression |
ISO |
Haloperidol results in decreased expression of NIFK protein |
CTD |
PMID:34122009 |
|
NCBI chr13:29,393,303...29,403,387
Ensembl chr13:29,393,286...29,405,896
|
|
G |
Nop14 |
NOP14 nucleolar protein |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of NOP14 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:76,081,318...76,102,454
Ensembl chr14:76,080,793...76,102,453
|
|
G |
Nop53 |
NOP53 ribosome biogenesis factor |
increases expression |
ISO |
Haloperidol results in increased expression of NOP53 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:76,629,084...76,636,902
Ensembl chr 1:76,629,069...76,636,902
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [Haloperidol results in increased expression of NOS2 mRNA] |
CTD |
PMID:30217539 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
affects activity |
EXP |
Haloperidol affects the activity of NPPA protein modified form |
CTD |
PMID:1363893 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nptx2 |
neuronal pentraxin 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of NPTX2 mRNA |
CTD |
PMID:18208916 |
|
NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345
|
|
G |
Npy |
neuropeptide Y |
multiple interactions decreases expression increases expression |
EXP |
Haloperidol promotes the reaction [Amphetamine results in decreased expression of NPY protein] Haloperidol results in decreased expression of NPY mRNA Haloperidol results in increased expression of NPY protein |
CTD |
PMID:7644023 PMID:15985714 PMID:16516965 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of NQO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Haloperidol results in increased expression of NR0B2 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
increases expression |
EXP |
Haloperidol results in increased expression of NR1D1 mRNA |
CTD |
PMID:11564422 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
affects response to substance decreases expression increases expression multiple interactions |
ISO EXP |
NR4A1 affects the susceptibility to Haloperidol Haloperidol results in decreased expression of NR4A1 mRNA Haloperidol results in increased expression of NR4A1 mRNA 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of NR4A1 mRNA] |
CTD |
PMID:10987852 PMID:11564422 PMID:14603264 PMID:19695244 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
increases expression |
EXP |
Haloperidol results in increased expression of NR4A3 mRNA |
CTD |
PMID:19695244 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
EXP |
Haloperidol results in increased expression of NRG1 protein |
CTD |
PMID:18184445 PMID:26961615 |
|
NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
decreases expression |
EXP ISO |
Haloperidol results in decreased expression of NSF mRNA Haloperidol results in decreased expression of NSF protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nts |
neurotensin |
multiple interactions increases expression |
ISO EXP |
SLC6A3 protein promotes the reaction [Haloperidol results in increased expression of NTS mRNA] 8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of NTS mRNA]; Theophylline inhibits the reaction [Haloperidol results in increased expression of NTS mRNA] Haloperidol results in increased expression of NTS mRNA; Haloperidol results in increased expression of NTS protein |
CTD |
PMID:10199625 PMID:11120399 PMID:11602683 PMID:12887421 PMID:14603264 PMID:14698760 More...
|
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Numbl |
NUMB-like, endocytic adaptor protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of NUMBL mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 1:82,549,814...82,573,788
Ensembl chr 1:82,550,054...82,573,776
|
|
G |
Nup54 |
nucleoporin 54 |
decreases expression |
ISO |
Haloperidol results in decreased expression of NUP54 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,617,630...15,636,029
Ensembl chr14:15,617,679...15,636,028
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Haloperidol results in increased expression of NUPR1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:181,213,292...181,215,327
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of OAT protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
affects response to substance |
ISO |
OPRL1 affects the susceptibility to Haloperidol |
CTD |
PMID:16237164 |
|
NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
OPRM1 protein inhibits the reaction [Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]] |
CTD |
PMID:20184921 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Osbpl8 |
oxysterol binding protein-like 8 |
increases expression |
ISO |
Haloperidol results in increased expression of OSBPL8 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:46,596,944...46,749,888
Ensembl chr 7:46,596,983...46,749,888
|
|
G |
Park7 |
Parkinsonism associated deglycase |
increases expression |
ISO |
Haloperidol results in increased expression of PARK7 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Pcmt1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PCMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:2,111,756...2,160,354
Ensembl chr 1:2,111,763...2,159,201
|
|
G |
Pcsk1n |
proprotein convertase subtilisin/kexin type 1 inhibitor |
increases expression |
ISO |
Haloperidol results in increased expression of PCSK1N mRNA |
CTD |
PMID:14647396 |
|
NCBI chr X:14,580,036...14,583,478
Ensembl chr X:14,580,038...14,583,566
|
|
G |
Pde10a |
phosphodiesterase 10A |
increases expression |
EXP |
Haloperidol results in increased expression of PDE10A mRNA; Haloperidol results in increased expression of PDE10A protein |
CTD |
PMID:18222493 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde1b |
phosphodiesterase 1B |
increases expression |
EXP ISO |
Haloperidol results in increased expression of PDE1B mRNA; Haloperidol results in increased expression of PDE1B protein |
CTD |
PMID:14647396 PMID:18222493 |
|
NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580
|
|
G |
Pde4a |
phosphodiesterase 4A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PDE4A protein |
CTD |
PMID:20222156 |
|
NCBI chr 8:19,706,649...19,751,937
Ensembl chr 8:19,703,290...19,751,961
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PDLIM5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pdzrn3 |
PDZ domain containing RING finger 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PDZRN3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:133,770,736...133,996,959
Ensembl chr 4:133,770,736...133,996,959
|
|
G |
Penk |
proenkephalin |
multiple interactions increases expression |
ISO EXP |
3,4-dicarboxyphenylglycine promotes the reaction [Haloperidol results in increased expression of PENK mRNA]; Docosahexaenoic Acids inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Tretinoin inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] 1-aminocyclopentane-1,2,4-tricarboxylic acid inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 1-aminoindan-1,5-dicarboxylic acid inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 2-(2,3-dicarboxycyclopropyl)glycine promotes the reaction [Haloperidol results in increased expression of PENK mRNA]; 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Memantine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Scopolamine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] Haloperidol results in increased expression of PENK mRNA; Haloperidol results in increased expression of PENK protein |
CTD |
PMID:3838946 PMID:7637876 PMID:12373537 PMID:12727308 PMID:12834887 PMID:12887421 PMID:14603264 PMID:14642644 PMID:15215559 PMID:17224239 More...
|
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Per1 |
period circadian regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PER1 mRNA |
CTD |
PMID:27746588 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Pfdn5 |
prefoldin subunit 5 |
increases expression |
ISO |
Haloperidol results in increased expression of PFDN5 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:133,451,778...133,456,516
Ensembl chr 7:133,451,453...133,456,516
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression multiple interactions |
EXP ISO |
Haloperidol results in increased expression of PFKP mRNA [Cuprizone co-treated with Haloperidol] results in increased expression of PFKP protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr17:63,729,743...63,794,021
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PFN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of PGK1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Phactr1 |
phosphatase and actin regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PHACTR1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr17:21,560,364...22,040,166
Ensembl chr17:21,562,721...22,039,831
|
|
G |
Picalm |
phosphatidylinositol binding clathrin assembly protein |
decreases expression |
EXP |
Haloperidol results in decreased expression of PICALM mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:144,056,415...144,138,045
Ensembl chr 1:144,056,721...144,137,557
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PIK3R3 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583
|
|
G |
Pkib |
cAMP-dependent protein kinase inhibitor beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PKIB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr20:36,965,172...37,062,190
Ensembl chr20:36,905,340...37,062,187
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
EXP |
Haloperidol results in increased expression of PKM mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plp1 |
proteolipid protein 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PLP1 mRNA |
CTD |
PMID:17177202 PMID:18797397 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Plpbp |
pyridoxal phosphate binding protein |
increases expression |
ISO |
Haloperidol results in increased expression of PROSC protein |
CTD |
PMID:34122009 |
|
NCBI chr16:65,003,292...65,014,886
Ensembl chr16:65,002,223...65,014,886
|
|
G |
Pls3 |
plastin 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PLS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Pmpca |
peptidase, mitochondrial processing subunit alpha |
increases expression |
ISO |
Haloperidol results in increased expression of PMPCA protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:9,207,731...9,216,846
Ensembl chr 3:9,207,717...9,216,844
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PPA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[Cannabidiol co-treated with Haloperidol] results in increased expression of PPARGC1A protein |
CTD |
PMID:30217539 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPM1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
|
|
G |
Ppm1b |
protein phosphatase, Mg2+/Mn2+ dependent, 1B |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPM1B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:9,646,695...9,707,471
Ensembl chr 6:9,655,765...9,707,974
|
|
G |
Ppm1f |
protein phosphatase, Mg2+/Mn2+ dependent, 1F |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of PPM1F protein |
CTD |
PMID:34122009 |
|
NCBI chr11:84,064,422...84,094,410
Ensembl chr11:84,064,420...84,094,340
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1CB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1CC mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:34,383,072...34,400,553
Ensembl chr12:34,383,072...34,400,553
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of PPP1R14B protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319
|
|
G |
Ppp1r1a |
protein phosphatase 1, regulatory (inhibitor) subunit 1A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:134,654,578...134,662,236
Ensembl chr 7:134,654,579...134,662,230
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
increases phosphorylation |
ISO |
Haloperidol results in increased phosphorylation of PPP1R1B protein |
CTD |
PMID:12871586 |
|
NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775
|
|
G |
Ppp1r2 |
protein phosphatase 1, regulatory (inhibitor) subunit 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr11:69,472,676...69,494,468
Ensembl chr11:69,472,555...69,494,463
|
|
G |
Ppp1r9b |
protein phosphatase 1, regulatory subunit 9B |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R9B protein |
CTD |
PMID:16844384 |
|
NCBI chr10:79,938,055...79,954,085
Ensembl chr10:79,938,066...79,954,083
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2CA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ppp2cb |
protein phosphatase 2 catalytic subunit beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2CB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
EXP |
Haloperidol results in increased expression of PPP2R1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2R2A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions decreases expression |
EXP |
[Haloperidol binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein Haloperidol results in decreased expression of PPP3CA mRNA; Haloperidol results in decreased expression of PPP3CA protein |
CTD |
PMID:16033416 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression multiple interactions |
ISO |
Haloperidol results in decreased expression of PPP5C mRNA [Cuprizone co-treated with Haloperidol] results in decreased expression of PPP5C protein |
CTD |
PMID:14647396 PMID:34122009 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
increases expression |
EXP |
Haloperidol results in increased expression of PRKACA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
increases expression |
EXP |
Haloperidol results in increased expression of PRKACB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions increases expression |
EXP ISO |
Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] Haloperidol results in increased expression of PRKAR2A mRNA; Haloperidol results in increased expression of PRKAR2A protein [Cuprizone co-treated with Haloperidol] results in decreased expression of PRKAR2A protein |
CTD |
PMID:11907174 PMID:34122009 |
|
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions decreases expression increases expression |
EXP |
Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] Haloperidol results in decreased expression of PRKAR2B mRNA Haloperidol results in increased expression of PRKAR2B mRNA; Haloperidol results in increased expression of PRKAR2B protein |
CTD |
PMID:11907174 PMID:15860345 |
|
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions increases expression |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of PRKCB protein Haloperidol results in increased expression of PRKCB mRNA |
CTD |
PMID:15860345 PMID:15967061 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkce |
protein kinase C, epsilon |
increases expression |
EXP |
Haloperidol results in increased expression of PRKCE mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prkcsh |
protein kinase C substrate 80K-H |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PRKCSH protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492
|
|
G |
Prkcz |
protein kinase C, zeta |
increases expression |
EXP |
Haloperidol results in increased expression of PRKCZ mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prl |
prolactin |
affects expression increases secretion increases expression multiple interactions |
ISO EXP |
Haloperidol affects the expression of PRL protein Haloperidol results in increased secretion of PRL protein Haloperidol results in increased expression of PRL protein Haloperidol inhibits the reaction [Aripiprazole results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [cabergoline results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Dopamine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [talipexole results in decreased secretion of PRL protein]; LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)- inhibits the reaction [Haloperidol results in increased expression of PRL protein]; Triptorelin Pamoate inhibits the reaction [Haloperidol results in increased expression of PRL protein] |
CTD |
PMID:1304992 PMID:1380082 PMID:2136057 PMID:3019639 PMID:3158510 PMID:3883215 PMID:3906589 PMID:7018927 PMID:7214106 PMID:7348089 PMID:7670571 PMID:8613910 PMID:8915564 PMID:9090331 PMID:9128918 PMID:9265911 PMID:9265916 PMID:9376336 PMID:9572212 PMID:10661492 PMID:11048906 PMID:11071396 PMID:11997696 PMID:15289996 PMID:15638391 PMID:16282852 PMID:18521575 More...
|
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prpf19 |
pre-mRNA processing factor 19 |
increases expression |
ISO |
Haloperidol results in increased expression of PRPF19 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:207,541,582...207,552,664
Ensembl chr 1:207,541,595...207,552,662
|
|
G |
Prpf38b |
pre-mRNA processing factor 38B |
decreases expression |
ISO |
Haloperidol results in decreased expression of PRPF38B mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:196,553,224...196,562,271
Ensembl chr 2:196,553,225...196,562,250
|
|
G |
Prrc2a |
proline-rich coiled-coil 2A |
decreases expression |
ISO |
Haloperidol results in decreased expression of PRRC2A mRNA |
CTD |
PMID:18797397 |
|
NCBI chr20:3,658,391...3,674,143
Ensembl chr20:3,658,695...3,674,130
|
|
G |
Prxl2a |
peroxiredoxin like 2A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PRXL2A protein |
CTD |
PMID:34122009 |
|
NCBI chr16:16,866,601...16,886,378
Ensembl chr16:16,866,603...16,886,433
|
|
G |
Psmb9 |
proteasome 20S subunit beta 9 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PSMB9 mRNA |
CTD |
PMID:16452686 |
|
NCBI chr20:4,667,044...4,672,512
Ensembl chr20:4,666,046...4,672,512
|
|
G |
Psmd12 |
proteasome 26S subunit, non-ATPase 12 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PSMD12 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Haloperidol results in increased expression of PTGS2 mRNA |
CTD |
PMID:30217539 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptma |
prothymosin alpha |
increases expression |
ISO |
Haloperidol results in increased expression of PTMA protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
|
|
G |
Ptms |
parathymosin |
increases expression |
ISO |
Haloperidol results in increased expression of PTMS mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:157,722,384...157,726,575
Ensembl chr 4:157,722,386...157,727,009
|
|
G |
Pura |
purine rich element binding protein A |
increases expression |
ISO |
Haloperidol results in increased expression of PURA protein |
CTD |
PMID:34122009 |
|
NCBI chr18:27,884,618...27,905,500
Ensembl chr18:27,884,556...27,905,513
|
|
G |
Purb |
purine rich element binding protein B |
decreases expression |
ISO |
Haloperidol results in decreased expression of PURB protein |
CTD |
PMID:34122009 |
|
NCBI chr14:81,342,374...81,344,857
Ensembl chr14:81,336,448...81,351,432
|
|
G |
Pvalb |
parvalbumin |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [Phencyclidine results in decreased expression of PVALB mRNA] |
CTD |
PMID:12589379 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Pycr1 |
pyrroline-5-carboxylate reductase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PYCR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:105,917,732...105,922,658
Ensembl chr10:105,917,680...105,922,549
|
|
G |
Pygm |
glycogen phosphorylase, muscle associated |
decreases expression |
ISO |
Haloperidol results in decreased expression of PYGM protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368
|
|
G |
Qki |
QKI, KH domain containing RNA binding |
increases expression |
ISO |
Haloperidol results in increased expression of QKI mRNA alternative form |
CTD |
PMID:19335891 |
|
NCBI chr 1:50,387,698...50,501,568
Ensembl chr 1:50,387,698...50,498,831
|
|
G |
Rab10 |
RAB10, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB10 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:26,267,081...26,319,739
Ensembl chr 6:26,266,859...26,320,193
|
|
G |
Rab11a |
RAB11a, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB11A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:65,223,698...65,246,461
Ensembl chr 8:65,222,949...65,246,525
|
|
G |
Rab12 |
RAB12, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB12 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 9:106,480,301...106,506,895
Ensembl chr 9:106,480,301...106,506,910
|
|
G |
Rab28 |
RAB28, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB28 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:69,245,846...69,322,968
Ensembl chr14:69,245,854...69,322,967
|
|
G |
Rab4a |
RAB4A, member RAS oncogene family |
decreases expression |
EXP |
Haloperidol results in decreased expression of RAB4A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:51,795,613...51,822,706
Ensembl chr19:51,795,613...51,822,703
|
|
G |
Rab5a |
RAB5A, member RAS oncogene family |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RAB5A protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:6,483,906...6,512,877
Ensembl chr 9:6,484,469...6,512,873
|
|
G |
Rab6a |
RAB6A, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB6A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
decreases expression |
EXP |
Haloperidol results in decreased expression of RAB7A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
|
|
G |
Rab8a |
RAB8A, member RAS oncogene family |
decreases expression |
EXP |
Haloperidol results in decreased expression of RAB8A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678
|
|
G |
Rac1 |
Rac family small GTPase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of RAC1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rala |
RAS like proto-oncogene A |
increases expression |
EXP |
Haloperidol results in increased expression of RALA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:47,092,139...47,145,192
Ensembl chr17:47,092,207...47,144,063
|
|
G |
Ralb |
RAS like proto-oncogene B |
increases expression |
EXP |
Haloperidol results in increased expression of RALB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:30,588,036...30,624,199
Ensembl chr13:30,588,033...30,624,202
|
|
G |
Ranbp3 |
RAN binding protein 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of RANBP3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:1,507,233...1,544,460
Ensembl chr 9:1,507,361...1,544,460
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAP1B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:53,423,039...53,456,388
Ensembl chr 7:53,423,130...53,456,370
|
|
G |
Rapgef4 |
Rap guanine nucleotide exchange factor 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RAPGEF4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316
|
|
G |
Rarb |
retinoic acid receptor, beta |
increases expression |
EXP |
Haloperidol results in increased expression of RARB mRNA alternative form |
CTD |
PMID:11564422 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rasgrf1 |
RAS protein-specific guanine nucleotide-releasing factor 1 |
affects localization |
EXP |
Haloperidol affects the localization of RASGRF1 protein |
CTD |
PMID:17092607 |
|
NCBI chr 8:90,445,154...90,574,274
Ensembl chr 8:90,445,154...90,574,269
|
|
G |
Rasgrp1 |
RAS guanyl releasing protein 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of RASGRP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:104,168,549...104,230,107
Ensembl chr 3:104,170,013...104,230,056
|
|
G |
Rcn1 |
reticulocalbin 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RCN1 protein Haloperidol results in decreased expression of RCN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:91,841,052...91,855,295
Ensembl chr 3:91,841,052...91,855,295
|
|
G |
Rdh11 |
retinol dehydrogenase 11 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RDH11 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252
|
|
G |
Rdx |
radixin |
decreases expression |
ISO |
Haloperidol results in decreased expression of RDX protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:52,379,494...52,437,673
Ensembl chr 8:52,379,494...52,437,678
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression |
EXP |
Haloperidol results in increased expression of RELA protein |
CTD |
PMID:18554768 PMID:18590723 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Reln |
reelin |
decreases expression |
EXP |
Haloperidol results in decreased expression of RELN mRNA; Haloperidol results in decreased expression of RELN protein |
CTD |
PMID:19359144 |
|
NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
EXP |
Haloperidol results in increased expression of RGS2 mRNA |
CTD |
PMID:11409749 PMID:11516571 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
increases expression |
EXP |
Haloperidol results in increased expression of RGS4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Rgs8 |
regulator of G-protein signaling 8 |
increases expression |
EXP |
Haloperidol results in increased expression of RGS8 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:65,804,703...65,848,953
Ensembl chr13:65,804,797...65,846,807
|
|
G |
Rgs9 |
regulator of G-protein signaling 9 |
affects response to substance |
ISO |
RGS9 affects the susceptibility to Haloperidol |
CTD |
PMID:15728856 |
|
NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892
|
|
G |
Rhoa |
ras homolog family member A |
decreases expression |
EXP |
Haloperidol results in decreased expression of RHOA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rims1 |
regulating synaptic membrane exocytosis 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of RIMS1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:24,696,959...25,196,368
Ensembl chr 9:24,698,854...25,196,631
|
|
G |
Rorb |
RAR-related orphan receptor B |
decreases expression |
EXP |
Haloperidol results in decreased expression of RORB mRNA |
CTD |
PMID:11564422 |
|
NCBI chr 1:216,363,629...216,544,390
Ensembl chr 1:216,363,629...216,544,390
|
|
G |
Rpl13 |
ribosomal protein L13 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RPL13 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:51,153,990...51,156,541
Ensembl chr19:51,153,924...51,163,014
|
|
G |
Rpl18a |
ribosomal protein L18A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RPL18A protein |
CTD |
PMID:34122009 |
|
NCBI chr16:18,542,572...18,544,578
Ensembl chr16:18,542,566...18,545,546
|
|
G |
Rpl19 |
ribosomal protein L19 |
decreases expression multiple interactions |
ISO |
Haloperidol results in decreased expression of RPL19 protein [Cuprizone co-treated with Haloperidol] results in increased expression of RPL19 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112
|
|
G |
Rpl30 |
ribosomal protein L30 |
increases expression |
ISO |
Haloperidol results in increased expression of RPL30 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:65,648,470...65,651,363
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
|
|
G |
Rpl6 |
ribosomal protein L6 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RPL6 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921
|
|
G |
Rpl8 |
ribosomal protein L8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RPL8 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482
|
|
G |
Rplp0l1 |
ribosomal protein lateral stalk subunit P0 like 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RPLP0P6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:191,921,503...191,922,661
Ensembl chr 2:191,921,574...191,922,646
|
|
G |
Rplp2 |
ribosomal protein lateral stalk subunit P2 |
increases expression |
ISO |
Haloperidol results in increased expression of RPLP2 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:196,546,086...196,548,636
Ensembl chr 1:196,546,352...196,548,645
|
|
G |
Rps10 |
ribosomal protein S10 |
increases expression |
ISO |
Haloperidol results in increased expression of RPS10 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:5,694,313...5,698,922
Ensembl chr20:5,694,313...5,699,044
|
|
G |
Rps16 |
ribosomal protein S16 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RPS16 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:83,643,066...83,646,056
Ensembl chr 1:83,643,130...83,646,206
|
|
G |
Rps27 |
ribosomal protein S27 |
increases expression |
ISO |
Haloperidol results in increased expression of RPS27 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
|
|
G |
Rps27a |
ribosomal protein S27a |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RPS27A protein |
CTD |
PMID:34122009 |
|
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011
|
|
G |
Rps9 |
ribosomal protein S9 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RPS9 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,511,723...65,515,121
Ensembl chr 1:65,511,723...65,515,123
|
|
G |
Rrad |
RRAD, Ras related glycolysis inhibitor and calcium channel regulator |
increases expression |
EXP |
Haloperidol results in increased expression of RRAD mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:354,184...357,424
Ensembl chr19:354,198...357,417
|
|
G |
Rrbp1 |
ribosome binding protein 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RRBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:131,314,996...131,376,930
Ensembl chr 3:131,314,998...131,376,981
|
|
G |
Rsf1 |
remodeling and spacing factor 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of RSF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:151,892,055...152,015,089
Ensembl chr 1:151,892,434...152,009,051
|
|
G |
Rtn4 |
reticulon 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of RTN4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects response to substance increases expression |
ISO EXP |
RXRG protein affects the susceptibility to Haloperidol Haloperidol results in increased expression of RXRG mRNA alternative form |
CTD |
PMID:10336693 PMID:11564422 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
decreases expression |
ISO |
Haloperidol results in decreased expression of S100A9 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of SAE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Sars1 |
seryl-tRNA synthetase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of SARS protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:196,065,543...196,081,240
Ensembl chr 2:196,065,430...196,081,277
|
|
G |
Satb2 |
SATB homeobox 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of SATB2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:58,348,027...58,534,256
Ensembl chr 9:58,350,246...58,530,707
|
|
G |
Sbds |
Sbds, ribosome maturation factor |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of SBDS protein |
CTD |
PMID:34122009 |
|
NCBI chr12:26,420,410...26,429,650
Ensembl chr12:26,420,414...26,429,649
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
ISO |
Haloperidol results in increased expression of SC5D mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Haloperidol results in increased expression of SCD mRNA |
CTD |
PMID:16027736 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sec61a1 |
SEC61 translocon subunit alpha 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of SEC61A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:120,973,519...120,987,871
Ensembl chr 4:120,960,626...120,987,925
|
|
G |
Sec63 |
SEC63 homolog, protein translocation regulator |
increases expression |
ISO |
Haloperidol results in increased expression of SEC63 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:46,245,101...46,314,055
Ensembl chr20:46,245,101...46,314,055
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
increases expression |
ISO |
Haloperidol results in increased expression of SERPINA3 mRNA; Haloperidol results in increased expression of SERPINA3 protein |
CTD |
PMID:17175557 PMID:34122009 |
|
NCBI chr 6:123,323,632...123,331,166
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Serpini1 |
serpin family I member 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of SERPINI1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:160,346,758...160,433,135
|
|
G |
Sf3b4 |
splicing factor 3B subunit 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of SF3B4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:183,732,791...183,737,545
Ensembl chr 2:183,732,754...183,737,959
|
|
G |
Sgcd |
sarcoglycan, delta |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of SGCD protein |
CTD |
PMID:34122009 |
|
NCBI chr10:31,346,480...32,328,364
Ensembl chr10:31,280,511...31,724,840
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of SGK1 mRNA |
CTD |
PMID:16452686 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sh3kbp1 |
SH3 domain-containing kinase-binding protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of SH3KBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:34,877,862...35,223,013
Ensembl chr X:34,877,866...35,222,747
|
|
G |
Sh3pxd2b |
SH3 and PX domains 2B |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of SH3PXD2B protein |
CTD |
PMID:34122009 |
|
NCBI chr10:16,918,611...17,027,499
Ensembl chr10:16,918,679...17,005,170
|
|
G |
Slc17a6 |
solute carrier family 17 member 6 |
increases expression |
ISO |
Haloperidol results in increased expression of SLC17A6 mRNA; Haloperidol results in increased expression of SLC17A6 protein |
CTD |
PMID:18155072 |
|
NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
affects response to substance |
ISO |
SLC17A8 protein affects the susceptibility to Haloperidol |
CTD |
PMID:18278042 |
|
NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:23,994,217...24,048,079
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
affects binding |
ISO |
Haloperidol binds to SLC18A2 protein |
CTD |
PMID:7912402 |
|
NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
|
|
G |
Slc1a1 |
solute carrier family 1 member 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SLC1A1 mRNA |
CTD |
PMID:12873733 |
|
NCBI chr 1:226,549,932...226,631,925
Ensembl chr 1:226,549,842...226,630,402
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:12873733 |
|
NCBI chr 3:89,005,129...89,126,498
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SLC1A3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Haloperidol inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:23770354 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc25a3 |
solute carrier family 25 member 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of SLC25A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:25,611,937...25,619,401
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases expression |
ISO |
Haloperidol results in increased expression of SLC2A4 mRNA |
CTD |
PMID:16002093 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc39a7 |
solute carrier family 39 member 7 |
increases expression |
ISO |
Haloperidol results in increased expression of SLC39A7 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:4,823,166...4,826,538
Ensembl chr20:4,822,012...4,826,537
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions increases expression |
ISO EXP |
SLC6A3 protein promotes the reaction [Haloperidol results in increased expression of NTS mRNA] Haloperidol results in increased expression of SLC6A3 protein |
CTD |
PMID:14698760 PMID:17069804 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
increases expression |
EXP |
Haloperidol results in increased expression of SLC6A4 |
CTD |
PMID:12007678 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects response to substance affects expression |
ISO EXP |
SNAP25 gene SNP affects the susceptibility to Haloperidol Haloperidol affects the expression of SNAP25 mRNA |
CTD |
PMID:15823421 PMID:15860345 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Snrpd2 |
small nuclear ribonucleoprotein D2 polypeptide |
increases expression |
ISO |
Haloperidol results in increased expression of SNRPD2 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:78,798,377...78,801,227
Ensembl chr 1:78,798,377...78,803,351
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression multiple interactions decreases expression |
EXP |
Haloperidol results in increased expression of SOD1 mRNA Clozapine inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]; Haloperidol results in decreased activity of and results in decreased expression of SOD1 protein; olanzapine inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein] |
CTD |
PMID:12482469 PMID:12752374 PMID:16564057 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
EXP |
Haloperidol results in decreased expression of SOD2 mRNA; Haloperidol results in decreased expression of SOD2 protein Haloperidol results in decreased activity of and results in decreased expression of SOD2 protein |
CTD |
PMID:12482469 PMID:15860345 PMID:16564057 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
increases expression |
EXP |
Haloperidol results in increased expression of SOD3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Speg |
striated muscle enriched protein kinase |
increases expression |
ISO |
Haloperidol results in increased expression of SPEG protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:76,865,714...76,923,170
Ensembl chr 9:76,865,754...76,923,144
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Haloperidol results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:17052361 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srpra |
SRP receptor subunit alpha |
decreases expression |
ISO |
Haloperidol results in decreased expression of SRPRA protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:33,560,365...33,566,458
Ensembl chr 8:33,560,348...33,566,470
|
|
G |
Srsf2 |
serine and arginine rich splicing factor 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of SRSF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:102,052,158...102,055,365
Ensembl chr10:102,052,314...102,055,338
|
|
G |
Srsf5 |
serine and arginine rich splicing factor 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of SRSF5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of STIP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:204,209,434...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Strn4 |
striatin 4 |
increases expression |
ISO |
Haloperidol results in increased expression of STRN4 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:77,482,267...77,511,862
Ensembl chr 1:77,482,094...77,511,858
|
|
G |
Stt3a |
STT3 oligosaccharyltransferase complex catalytic subunit A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of STT3A protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:36,443,623...36,483,111
Ensembl chr 8:36,446,788...36,483,293
|
|
G |
Stx1a |
syntaxin 1A |
increases expression |
EXP |
Haloperidol results in increased expression of STX1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930
|
|
G |
Stx1b |
syntaxin 1B |
affects expression |
EXP |
Haloperidol affects the expression of STX1B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:182,415,544...182,434,385
Ensembl chr 1:182,415,546...182,441,280
|
|
G |
Stx4 |
syntaxin 4 |
increases expression |
EXP |
Haloperidol results in increased expression of STX4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:182,451,108...182,459,701
Ensembl chr 1:182,451,117...182,459,979
|
|
G |
Stx5 |
syntaxin 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of STX5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:205,637,401...205,653,563
Ensembl chr 1:205,637,413...205,653,563
|
|
G |
Stx7 |
syntaxin 7 |
decreases expression |
EXP |
Haloperidol results in decreased expression of STX7 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:21,197,075...21,237,320
Ensembl chr 1:21,197,075...21,237,279
|
|
G |
Stx8 |
syntaxin 8 |
affects expression |
EXP |
Haloperidol affects the expression of STX8 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:52,655,643...52,900,048
Ensembl chr10:52,654,990...52,894,993
|
|
G |
Supt3h |
SPT3 homolog, SAGA and STAGA complex component |
increases expression |
EXP |
Haloperidol results in increased expression of SUPT3H mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 9:15,878,296...16,206,768
Ensembl chr 9:15,868,287...16,206,706
|
|
G |
Syn2 |
synapsin II |
increases expression |
EXP |
Haloperidol results in increased expression of SYN2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:148,178,846...148,347,010
Ensembl chr 4:148,186,270...148,344,192
|
|
G |
Sypl1 |
synaptophysin-like 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of SYPL mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 6:49,565,111...49,585,205
Ensembl chr 6:49,565,154...49,585,330
|
|
G |
Syt11 |
synaptotagmin 11 |
increases expression |
EXP |
Haloperidol results in increased expression of SYT11 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964
|
|
G |
Syt3 |
synaptotagmin 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of SYT3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:94,880,835...94,895,518
Ensembl chr 1:94,881,247...94,895,246
|
|
G |
Syt4 |
synaptotagmin 4 |
affects expression |
EXP |
Haloperidol affects the expression of SYT4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr18:23,036,973...23,046,380
Ensembl chr18:23,038,378...23,046,332
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases expression |
EXP |
Haloperidol results in increased expression of TAC1 mRNA |
CTD |
PMID:10974607 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Haloperidol results in decreased expression of TAGLN mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tagln2 |
transgelin 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of TAGLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
decreases expression |
EXP |
Haloperidol results in decreased expression of TAP1 mRNA |
CTD |
PMID:16452686 |
|
NCBI chr20:4,656,262...4,666,634
Ensembl chr20:4,656,263...4,666,901
|
|
G |
Tatdn1 |
TatD DNase domain containing 1 |
increases expression |
ISO |
Haloperidol results in increased expression of TATDN1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:90,451,025...90,481,000
Ensembl chr 7:90,441,079...90,481,133
|
|
G |
Tcaf1 |
TRPM8 channel-associated factor 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of TCAF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:71,589,674...71,639,309
Ensembl chr 4:71,591,200...71,613,309
|
|
G |
Tcerg1 |
transcription elongation regulator 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of TCERG1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:34,505,708...34,566,470
Ensembl chr18:34,505,751...34,566,470
|
|
G |
Tf |
transferrin |
decreases expression |
ISO |
Haloperidol results in decreased expression of TRF mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tgoln2 |
trans-golgi network protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of TGOLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
Haloperidol results in increased expression of TH protein |
CTD |
PMID:17028028 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thra |
thyroid hormone receptor alpha |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of THRA mRNA alternative form Haloperidol results in increased expression of THRA mRNA alternative form |
CTD |
PMID:11564422 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tln2 |
talin 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of TLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:67,830,920...68,252,223
Ensembl chr 8:67,834,326...68,252,219
|
|
G |
Tm9sf2 |
transmembrane 9 superfamily member 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of TM9SF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:99,201,556...99,254,054
Ensembl chr15:99,201,489...99,254,049
|
|
G |
Tmem109 |
transmembrane protein 109 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of TMEM109 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:207,519,628...207,530,245
Ensembl chr 1:207,519,624...207,530,215
|
|
G |
Tmod3 |
tropomodulin 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of TMOD3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:76,248,978...76,310,855
Ensembl chr 8:76,248,979...76,310,977
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP ISO |
Haloperidol affects the reaction [Phencyclidine affects the expression of TNF mRNA] Haloperidol results in increased expression of TNF protein Haloperidol results in increased expression of TNF mRNA Cannabidiol inhibits the reaction [Haloperidol results in increased expression of TNF mRNA] |
CTD |
PMID:16478754 PMID:18554768 PMID:18590723 PMID:30217539 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnik |
TRAF2 and NCK interacting kinase |
decreases expression |
ISO |
Haloperidol results in decreased expression of TNIK mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:111,184,352...111,587,993
Ensembl chr 2:111,184,387...111,580,750
|
|
G |
Tor1a |
torsin family 1, member A |
affects response to substance |
ISO |
TOR1A gene mutant form affects the susceptibility to Haloperidol |
CTD |
PMID:20227500 |
|
NCBI chr 3:14,250,667...14,257,704
Ensembl chr 3:14,250,676...14,257,691
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
EXP |
Haloperidol results in increased expression of TP53 mRNA; Haloperidol results in increased expression of TP53 protein |
CTD |
PMID:16462815 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of TPI1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Trim2 |
tripartite motif-containing 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of TRIM2 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:169,500,628...169,652,855
Ensembl chr 2:169,500,634...169,652,927
|
|
G |
Trim23 |
tripartite motif-containing 23 |
decreases expression |
EXP |
Haloperidol results in decreased expression of TRIM23 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:35,302,405...35,335,746
En |